Overview

A Phase 4 Study of Brodalumab (KHK4827) in Subjects With Moderate to Severe Plaque Psoriasis

Status:
Withdrawn
Trial end date:
2022-11-01
Target enrollment:
Participant gender:
Summary
The objective of this study is assessing the efficacy and safety of brodalumab in Chinese subjects with moderate to severe plaque psoriasis.
Phase:
Phase 4
Details
Lead Sponsor:
Kyowa Kirin Co., Ltd.
Collaborator:
Kyowa Hakko Kirin China Pharmaceutical Co., LTD.
Treatments:
Brodalumab